Latest Articles

EAS guidance regarding combining Lipid-modifying therapy

PCSK9i and Prevention of CVD

The synopsis of a Cochrane Systematic review on PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.

PCSK9 Inhibitors in Cardiovascular Disease

PCSK9i after hospital discharge for acute MI

Lipid-Lowering Therapy and Achievement of Lipid Targets ESC and EAS Guidelines

LLTs and Antithrombotic Therapy in PAD

LLTs Exposure Time and Major Vascular Risk Reduction

Possible Challenges Post One Year of ESC/EAS Guidelines

Prognostic impact of achieving LDL cholesterol guidelines